These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31544947)

  • 21. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study.
    Hansen TB; Gram J; Bjerre P; Hagen C; Bollerslev J
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):323-9. PubMed ID: 7955439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in concentrations of circulating fibroblast activation protein alpha are associated with myocardial damage in patients with acute ST-elevation MI.
    Tillmanns J; Fraccarollo D; Galuppo P; Wollert KC; Bauersachs J
    Int J Cardiol; 2017 Apr; 232():155-159. PubMed ID: 28082091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity.
    Frajese GV; Taylor NF; Jenkins PJ; Besser GM; Monson JP
    Horm Res; 2004; 61(5):246-51. PubMed ID: 15004437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway.
    Díaz-Delfín J; Hondares E; Iglesias R; Giralt M; Caelles C; Villarroya F
    Endocrinology; 2012 Sep; 153(9):4238-45. PubMed ID: 22778214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating soluble fibroblast activation protein (FAP) levels are independent of cardiac and extra-cardiac FAP expression determined by targeted molecular imaging in patients with myocardial FAP activation.
    Tillmanns J; Weiglein JM; Neuser J; Fraccarollo D; Galuppo P; König T; Diekmann J; Ross T; Bengel FM; Bauersachs J; Derlin T
    Int J Cardiol; 2024 Jul; 406():132044. PubMed ID: 38614364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
    Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
    Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of growth hormone on circulating fibroblast growth factor 21 levels in humans.
    Lundberg J; Höybye C; Krusenstjerna-Hafstrøm T; Bina HA; Kharitonenkov A; Angelin B; Rudling M
    J Intern Med; 2013 Sep; 274(3):227-32. PubMed ID: 23844970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excessively high soluble Klotho in patients with acromegaly.
    Sze L; Bernays RL; Zwimpfer C; Wiesli P; Brändle M; Schmid C
    J Intern Med; 2012 Jul; 272(1):93-7. PubMed ID: 22452701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn's Disease Strictures Ex Vivo.
    Truffi M; Sorrentino L; Monieri M; Fociani P; Mazzucchelli S; Bonzini M; Zerbi P; Sampietro GM; Di Sabatino A; Corsi F
    Inflamm Bowel Dis; 2018 Jan; 24(2):332-345. PubMed ID: 29361086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene.
    Schmid C; Krayenbuehl PA; Bernays RL; Zwimpfer C; Maly FE; Wiesli P
    Clin Chem; 2007 Aug; 53(8):1484-8. PubMed ID: 17573420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate.
    Wu S; Levenson A; Kharitonenkov A; De Luca F
    J Biol Chem; 2012 Jul; 287(31):26060-7. PubMed ID: 22696219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue.
    Markan KR; Naber MC; Small SM; Peltekian L; Kessler RL; Potthoff MJ
    Mol Metab; 2017 Jun; 6(6):602-610. PubMed ID: 28580290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
    Drake WM; Rowles SV; Roberts ME; Fode FK; Besser GM; Monson JP; Trainer PJ
    Eur J Endocrinol; 2003 Dec; 149(6):521-7. PubMed ID: 14640992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly.
    Olarescu NC; Ueland T; Lekva T; Dahl TB; Halvorsen B; Aukrust P; Bollerslev J
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1355-62. PubMed ID: 22319029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU; Post KD; Powell JS; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble delta-like 1 homolog decreases in patients with acromegaly following pituitary surgery: A potential mediator of adipogenesis suppression by growth hormone?
    Sze L; Tschopp O; Neidert MC; Bernays RL; Ghirlanda C; Zwimpfer C; Wiesli P; Schmid C
    Growth Horm IGF Res; 2019 Apr; 45():20-24. PubMed ID: 30818110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.